Home › Companies › Cytokinetics, Incorporated › 2025-2026

Cytokinetics, Incorporated 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Cytokinetics, Incorporated’s Form 8-K, filed May 27, 2026 (Item 5.07 on EDGAR). Page generated November 1, 2026.

6Ballot items
413Asset managers
3,536Fund votes
May 27, 2026Meeting date

Results at a glance

Meeting of May 27, 2026: 6 items on Cytokinetics, Incorporated’s Form 8-K, filed May 27, 2026: 3 approved · 3 without a stated outcome.

Material dissent

Elect Director: Wendell Wierenga, Ph.D. 79% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Cytokinetics, Incorporated in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Cytokinetics, Incorporated

These tallies are Cytokinetics, Incorporated’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 27, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Cytokinetics, Incorporated — official shareholder meeting results, meeting held May 27, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Edward M. Kaye, M.D.	104,633,356	--	--	3,234,862	8,257,512	97%	Not verified	—
Elect Director: Wendell Wierenga, Ph.D.	85,427,010	--	--	22,441,208	8,257,512	79%	Not verified	—
Elect Director: Nancy J. Wysenski	104,820,911	--	--	3,047,307	8,257,512	97%	Not verified	—
2. Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2015 Employee Stock Purchase Plan by 1,000,000 shares of	107,254,415	261,354	352,449	--	8,257,512	99.7%	Approved	—
3. Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026	115,468,025	269,258	388,447	--	0	99.7%	Approved	—
4. Advisory Vote on Executive Compensation	104,005,531	3,018,095	844,592	--	8,257,512	97%	Approved	—

Source: Cytokinetics, Incorporated, Form 8-K, filed with the SEC on May 27, 2026 — read the filing on EDGAR.

How asset managers voted at the Cytokinetics, Incorporated 2025-2026 meeting

Each item below shows how the 413 asset managers that disclosed a Cytokinetics, Incorporated vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Edward M. Kaye, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 104,633,356WITHHELD: 3,234,862

Details: description as filed, official tally, votes by 109 asset managers

Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Edward M. Kaye, M.D.

Cytokinetics, Incorporated’s own tally for this item (“Elect Director: Edward M. Kaye, M.D.”): 104,633,356 for, 3,234,862 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 109 asset managers below reported 63,947,327 for, 1,637,297 withheld, 7 abstained, 119 not voted.

FOR

FOR: 63,947,327ABSTAIN: 7WITHHOLD: 1,637,297NOT VOTED: 119

Largest asset managers voting on “Election of Class I Directors for terms expiring in 2029: Edward M. Kaye, M.D.” at Cytokinetics, Incorporated, 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	16,283,015	7	0	For
T. Rowe Price	10,923,847	0	1,164,738	Mixed
Fidelity	11,423,245	0	0	For
BlackRock	8,039,816	0	0	For
Capital Group	2,351,843	0	0	For
State Street	1,952,001	0	0	For
Jackson National	1,888,383	0	0	For
Charles Schwab	1,381,375	0	0	For
Federated Hermes	698,221	0	0	For
Principal	497,274	0	48,873	Mixed
MUTUAL FUND SERIES TRUST	484,644	0	0	For
Voya	472,562	0	0	For
JPMorgan	469,912	0	0	For
PENN SERIES FUNDS INC	408,465	0	0	For
Equitable	205,840	0	199,733	Mixed
John Hancock	351,649	0	14,740	For
American Century	339,530	0	0	For
MFS	305,698	0	0	For
Goldman Sachs	281,731	0	0	For
FRANKLIN STRATEGIC SERIES	256,383	0	0	For
Columbia Threadneedle	255,713	0	0	For
TIAA	241,442	0	0	For
WILLIAM BLAIR FUNDS	228,990	0	0	For
Janus Detroit Street Trust	225,640	0	0	For
Brighthouse	176,250	0	48,275	Mixed

Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.

2. Elect Director: Nancy J. Wysenski

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 104,820,911WITHHELD: 3,047,307

Details: description as filed, official tally, votes by 109 asset managers

Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Nancy J. Wysenski

Cytokinetics, Incorporated’s own tally for this item (“Elect Director: Nancy J. Wysenski”): 104,820,911 for, 3,047,307 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 109 asset managers below reported 63,958,674 for, 1,625,951 withheld, 6 abstained, 119 not voted.

FOR

FOR: 63,958,674ABSTAIN: 6WITHHOLD: 1,625,951NOT VOTED: 119

Largest asset managers voting on “Election of Class I Directors for terms expiring in 2029: Nancy J. Wysenski” at Cytokinetics, Incorporated, 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	16,283,016	6	0	For
T. Rowe Price	10,923,847	0	1,164,738	Mixed
Fidelity	11,423,245	0	0	For
BlackRock	8,039,816	0	0	For
Capital Group	2,351,843	0	0	For
State Street	1,952,001	0	0	For
Jackson National	1,888,383	0	0	For
Charles Schwab	1,381,375	0	0	For
Federated Hermes	698,221	0	0	For
Principal	497,274	0	48,873	Mixed
MUTUAL FUND SERIES TRUST	484,644	0	0	For
Voya	472,562	0	0	For
JPMorgan	469,912	0	0	For
PENN SERIES FUNDS INC	408,465	0	0	For
Equitable	205,840	0	199,733	Mixed
John Hancock	351,649	0	14,740	For
American Century	339,530	0	0	For
MFS	305,698	0	0	For
Goldman Sachs	281,731	0	0	For
FRANKLIN STRATEGIC SERIES	256,383	0	0	For
Columbia Threadneedle	255,713	0	0	For
TIAA	241,442	0	0	For
WILLIAM BLAIR FUNDS	228,990	0	0	For
Janus Detroit Street Trust	225,640	0	0	For
Brighthouse	176,250	0	48,275	Mixed

Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.

3. Elect Director: Wendell Wierenga, Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD

FOR: 85,427,010WITHHELD: 22,441,208

Details: description as filed, official tally, votes by 109 asset managers

Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Wendell Wierenga, Ph.D.

Cytokinetics, Incorporated’s own tally for this item (“Elect Director: Wendell Wierenga, Ph.D.”): 85,427,010 for, 22,441,208 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 109 asset managers below reported 50,207,324 for, 15,377,264 withheld, 43 abstained, 119 not voted.

FORWITHHOLD

FOR: 50,207,324ABSTAIN: 43WITHHOLD: 15,377,264NOT VOTED: 119

Largest asset managers voting on “Election of Class I Directors for terms expiring in 2029: Wendell Wierenga, Ph.D.” at Cytokinetics, Incorporated, 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	16,276,543	43	6,436	For
T. Rowe Price	0	0	12,088,585	Withhold
Fidelity	11,423,245	0	0	For
BlackRock	8,039,816	0	0	For
Capital Group	2,351,843	0	0	For
State Street	1,951,905	0	96	For
Jackson National	315,606	0	1,572,777	Mixed
Charles Schwab	1,381,375	0	0	For
Federated Hermes	698,221	0	0	For
Principal	497,274	0	48,873	Mixed
MUTUAL FUND SERIES TRUST	484,644	0	0	For
Voya	472,562	0	0	For
JPMorgan	469,912	0	0	For
PENN SERIES FUNDS INC	26,151	0	382,314	Mixed
Equitable	205,840	0	199,733	Mixed
John Hancock	198,543	0	167,846	Mixed
American Century	339,530	0	0	For
MFS	305,698	0	0	For
Goldman Sachs	281,731	0	0	For
FRANKLIN STRATEGIC SERIES	256,383	0	0	For
Columbia Threadneedle	255,713	0	0	For
TIAA	241,442	0	0	For
WILLIAM BLAIR FUNDS	228,990	0	0	For
Janus Detroit Street Trust	225,640	0	0	For
Brighthouse	166,249	0	58,276	Mixed

Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.

4. 2. Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase…

Official resultCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.7% Approved · of votes cast

FOR 99.7%

FOR: 107,254,415AGAINST: 261,354

Details: description as filed, official tally, votes by 115 asset managers

Description as filed by funds: To approve the amendment and restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance thereunder by 1,000,000 shares of common stock.

Cytokinetics, Incorporated’s own tally for this item (“2. Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2015 Employee St”): 107,254,415 for, 261,354 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2015 Employee Stock Purchase Plan by 1,000,000 shares of common stock The stockholders…”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 115 asset managers below reported 65,793,645 for, 28,784 against, 1 abstained, 119 not voted.

FOR

FOR: 65,793,645AGAINST: 28,784ABSTAIN: 1NOT VOTED: 119

Largest asset managers voting on “To approve the amendment and restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Pl” at Cytokinetics, Incorporated, 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	16,283,021	0	1	For
T. Rowe Price	12,088,585	0	0	For
Fidelity	11,423,245	0	0	For
BlackRock	8,039,816	0	0	For
Capital Group	2,351,843	0	0	For
State Street	1,952,001	0	0	For
Jackson National	1,888,383	0	0	For
Charles Schwab	1,381,375	0	0	For
Federated Hermes	698,221	0	0	For
Principal	546,147	0	0	For
MUTUAL FUND SERIES TRUST	484,644	0	0	For
Voya	472,562	0	0	For
JPMorgan	469,912	0	0	For
PENN SERIES FUNDS INC	408,465	0	0	For
Equitable	405,573	0	0	For
John Hancock	366,389	0	0	For
American Century	339,530	0	0	For
MFS	305,698	0	0	For
Goldman Sachs	281,731	0	0	For
FRANKLIN STRATEGIC SERIES	256,383	0	0	For
Columbia Threadneedle	255,713	0	0	For
TIAA	241,442	0	0	For
WILLIAM BLAIR FUNDS	228,990	0	0	For
Janus Detroit Street Trust	225,640	0	0	For
Brighthouse	195,741	28,784	0	Mixed

Showing the 25 largest of 115 asset managers. See all 115 in the interactive database.

5. 4. Advisory Vote on Executive Compensation

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%

FOR: 104,005,531AGAINST: 3,018,095

Details: description as filed, official tally, votes by 412 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.

Cytokinetics, Incorporated’s own tally for this item (“4. Advisory Vote on Executive Compensation”): 104,005,531 for, 3,018,095 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4: Advisory Vote on Executive Compensation The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company's Proxy Statement for the 2026 Annual Meeting of Stockholders.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 107 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Cytokinetics, Incorporated, 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	16,283,016	4	1	For
T. Rowe Price	12,088,585	0	0	For
Fidelity	11,423,245	0	0	For
BlackRock	8,039,816	0	0	For
Capital Group	2,351,843	0	0	For
State Street	1,952,001	0	0	For
Jackson National	1,802,690	85,693	0	For
Charles Schwab	1,381,375	0	0	For
Federated Hermes	698,221	0	0	For
Principal	546,147	0	0	For
MUTUAL FUND SERIES TRUST	484,644	0	0	For
Voya	472,562	0	0	For
JPMorgan	469,912	0	0	For
PENN SERIES FUNDS INC	408,465	0	0	For
Equitable	405,573	0	0	For
John Hancock	366,389	0	0	For
American Century	339,530	0	0	For
MFS	305,698	0	0	For
Goldman Sachs	281,731	0	0	For
FRANKLIN STRATEGIC SERIES	256,383	0	0	For
Columbia Threadneedle	255,713	0	0	For
TIAA	241,442	0	0	For
WILLIAM BLAIR FUNDS	228,990	0	0	For
Janus Detroit Street Trust	225,640	0	0	For
Brighthouse	155,862	39,879	28,784	Mixed

Fund voting reports, all 107 managers: 65,136,666 for, 342,191 against, 28,785 abstained, 119 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 332 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Cytokinetics, Incorporated, 2025-2026
Asset manager	For	Against	Abstain	Vote
T. Rowe Price	18,395,855	0	0	For
Fidelity	9,986,518	0	0	For
Wellington	6,706,576	0	0	For
State Street	5,003,737	0	0	For
BlackRock	4,014,953	1,007	213	For
Polar Capital Holdings Plc	3,087,854	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,795,792	0	0	For
Avoro Capital Advisors LLC	1,746,254	0	0	For
Capital Group	1,586,734	0	0	For
Charles Schwab	1,397,102	0	0	For
Frazier Life Sciences Management, L.P.	1,159,879	0	0	For
Northern Trust	1,040,777	0	0	For
Vanguard	1,004,167	0	0	For
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	855,671	0	0	For
PRINCIPAL GLOBAL INVESTORS	786,678	0	0	For
Capital Research Global Investors	770,999	0	0	For
BNP Paribas Asset Management Holding S.A.	0	714,344	0	Against
MELLON INVESTMENTS Corp	702,646	0	0	For
Federated Hermes	698,831	622	0	For
RTW INVESTMENTS, LP	696,571	0	0	For
PICTET ASSET MANAGEMENT SA	682,881	0	0	For
Melqart Asset Management (UK) Ltd	615,007	0	0	For
BROWN ADVISORY INC	559,665	0	0	For
Voya	537,017	0	0	For
Foresite Capital Management IV, LLC	503,175	0	0	For

Institutional-manager reports, all 332 managers: 77,453,582 for, 2,273,009 against, 663,892 abstained, 1,954 not voted, 246,596 mixed. Showing the 25 largest; see all in the interactive database.

6. 3. Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.7% Approved · of votes cast

FOR 99.7%

FOR: 115,468,025AGAINST: 269,258

Details: description as filed, official tally, votes by 109 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Cytokinetics, Incorporated’s own tally for this item (“3. Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026”): 115,468,025 for, 269,258 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026 The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent reg…”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 109 asset managers below reported 65,555,751 for, 96 against, 28,785 abstained, 119 not voted.

FOR

FOR: 65,555,751AGAINST: 96ABSTAIN: 28,785NOT VOTED: 119

Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm ” at Cytokinetics, Incorporated, 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	16,283,021	0	1	For
T. Rowe Price	12,088,585	0	0	For
Fidelity	11,423,245	0	0	For
BlackRock	8,039,816	0	0	For
Capital Group	2,351,843	0	0	For
State Street	1,951,905	96	0	For
Jackson National	1,888,383	0	0	For
Charles Schwab	1,381,375	0	0	For
Federated Hermes	698,221	0	0	For
Principal	546,147	0	0	For
MUTUAL FUND SERIES TRUST	484,644	0	0	For
Voya	472,562	0	0	For
JPMorgan	469,912	0	0	For
PENN SERIES FUNDS INC	408,465	0	0	For
Equitable	405,573	0	0	For
John Hancock	366,389	0	0	For
American Century	339,530	0	0	For
MFS	305,698	0	0	For
Goldman Sachs	281,731	0	0	For
FRANKLIN STRATEGIC SERIES	256,383	0	0	For
Columbia Threadneedle	255,713	0	0	For
TIAA	241,442	0	0	For
WILLIAM BLAIR FUNDS	228,990	0	0	For
Janus Detroit Street Trust	225,640	0	0	For
Brighthouse	195,741	0	28,784	Mixed

Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.

Largest Cytokinetics, Incorporated shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 124,432,565 shares outstanding at the time of that meeting.

Fund voting reports: top Cytokinetics, Incorporated shareholders by shares voted on “To approve the amendment and restatement of the Company's Amended and Restated 2015 Employee…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	13.09%
2	T. Rowe Price	9.71%
3	Fidelity	9.18%
4	BlackRock	6.46%
5	Capital Group	1.89%
6	State Street	1.57%
7	Jackson National	1.52%
8	Charles Schwab	1.11%
9	Federated Hermes	0.56%
10	Principal	0.44%

Institutional-manager reports: top Cytokinetics, Incorporated shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2025-2026
#	Asset manager	% of shares outstanding
1	T. Rowe Price	14.78%
2	Fidelity	8.03%
3	Wellington	5.39%
4	State Street	4.02%
5	BlackRock	3.23%
6	Polar Capital Holdings Plc	2.48%
7	GEODE CAPITAL MANAGEMENT, LLC	2.25%
8	Avoro Capital Advisors LLC	1.40%
9	Capital Group	1.28%
10	Charles Schwab	1.12%

Reported Cytokinetics, Incorporated holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Cytokinetics, Incorporated holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	13.30%	13F
Entities affiliated with BlackRock, Inc.	12.26%	DEF14A
Entities affiliated with Fidelity Investments	10.53%	DEF14A
Vanguard Group	9.68%	13F
FMR (Fidelity)	8.62%	13F
Wellington Management	6.44%	13F
Entities affiliated with Wellington Management Group LLP	5.25%	DEF14A
State Street	4.62%	13F
Goldman Sachs	1.97%	13F
Robert I. Blum	1.32%	DEF14A

Percentages above are of 124,432,565 shares outstanding, as reported by Cytokinetics, Incorporated on its Form 10-Q dated May 4, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Cytokinetics, Incorporated’s 10-Q dated May 4, 2026. This page is a static snapshot rebuilt weekly on November 1, 2026; a live search always shows the current data.

At Cytokinetics, Incorporated's shareholder meeting held May 27, 2026, in the 2025-2026 proxy season, 413 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 3,536 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — Cytokinetics, Incorporated's filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Cytokinetics, Incorporated's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 27, 2026.

Cytokinetics, Incorporated proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.